HLA‐DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T‐Cell Exhaustion in HBV‐Associated Hepatocellular Carcinoma
Authors:
Open Access
- 4 June 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 12 (30) , e02979
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related deaths worldwide, with hepatitis B virus (HBV) as a major driver. Despite the pivotal role of viral infections in shaping the tumor microenvironment (TME), the mechanistic differences among HBV‐, hepatitis C virus (HCV)‐, and non‐B non‐C (NBNC)‐associated HCC remain poorly understood. By integrating the largest publicly available single‐cell RNA sequencing (scRNA‐seq) dataset of HCC (160 samples from 124 patients) with multi‐scale protein‐level validation using multiplex immunofluorescence and tissue microarrays (198 HCC specimens), HLA‐DR⁺ tumor cells are identified as a distinctive feature of HBV + HCC. These tumor cells uniquely express MHC class II molecules, typically restricted to antigen‐presenting cells, and correlate with immune checkpoint activation and PD‐L1 expression, potentially contributing to an immunosuppressive microenvironment specific to HBV + HCC. Trajectory analysis revealed distinct CD8⁺ T‐cell differentiation pathways in HBV + HCC, characterized by enhanced exhaustion and stem‐like phenotypes. HLA‐DR⁺ tumor cells are associated with increased recruitment of CD8⁺ T cells and correlated with T‐cell exhaustion, potentially contributing to a suppressive TME. Clinically, high proportions of HLA‐DR⁺ tumor cells are linked to poor survival outcomes, especially when accompanied by elevated PD‐L1 expression, suggesting that HLA‐DR⁺ tumor cells may serve as a potential predictive biomarker for immunotherapy efficacy in HCC. Collectively, the findings highlight HLA‐DR⁺ tumor cells as a distinctive feature of HBV‐associated HCC (HBV + HCC), providing novel insights into possible immunosuppressive mechanisms and therapeutic targets for immunotherapy in this disease context.Keywords
Funding Information
- National Natural Science Foundation of China (30900598)
- National Natural Science Foundation of China (82372896)
- National Natural Science Foundation of China (81872420)
- Health Commission of Henan Province (SBGJ202102043)
This publication has 40 references indexed in Scilit:
- Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapyJournal of the Formosan Medical Association, 2024
- Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysisHepatology International, 2024
- Systemic sterile induced-co-expression of IL-12 and IL-18 drive IFN-γ-dependent activation of microglia and recruitment of MHC-II-expressing inflammatory monocytes into the brainInternational Immunopharmacology, 2022
- Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinomaCell, 2021
- TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infectionJournal of Hepatology, 2020
- Integrated Proteogenomic Characterization of HBV-Related Hepatocellular CarcinomaCell, 2019
- Landscape and Dynamics of Single Immune Cells in Hepatocellular CarcinomaCell, 2019
- Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infectionJournal of Hepatology, 2017
- Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell SequencingCell, 2017
- HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patientsCancer Immunology, Immunotherapy, 2017